MannKind (MNKD) Stock Forecast, Price Target & Predictions
MNKD Stock Forecast
MannKind stock forecast is as follows: an average price target of $11.00 (represents a 55.15% upside from MNKD’s last price of $7.09) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
MNKD Price Target
The average price target for MannKind (MNKD) is $11.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $10.00. This represents a potential 55.15% upside from MNKD's last price of $7.09.
MNKD Analyst Ratings
According to 3 Wall Street analysts, MannKind's rating consensus is 'Buy'. The analyst rating breakdown for MNKD stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
MannKind Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 28, 2024 | Steven Lichtman | Oppenheimer | $12.00 | $5.38 | 123.05% | 69.25% |
| Oct 10, 2023 | Andreas Argyrides | Wedbush | $10.00 | $4.23 | 136.41% | 41.04% |
The latest MannKind stock forecast, released on Aug 28, 2024 by Steven Lichtman from Oppenheimer, set a price target of $12.00, which represents a 123.05% increase from the stock price at the time of the forecast ($5.38), and a 69.25% increase from MNKD last price ($7.09).
MannKind Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $12.00 | $12.00 |
| Last Closing Price | $7.09 | $7.09 | $7.09 |
| Upside/Downside | -100.00% | 69.25% | 69.25% |
In the current month, the average price target of MannKind stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MannKind's last price of $7.09. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 12, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Oct 10, 2023 | Wedbush | - | Outperform | Initialise |
MannKind's last stock rating was published by Oppenheimer on Aug 28, 2024. The company gave MNKD a "Outperform" rating, the same as its previous rate.
MannKind Financial Forecast
MannKind Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $58.47M | $51.25M | $48.61M | $40.63M | $36.06M | $32.83M | $18.89M | $11.99M | $12.52M | $22.21M | $23.28M | $17.44M | $18.44M | $15.35M | $15.11M | $16.23M | $15.99M | $14.60M | $15.00M | $17.45M | $3.46M | $3.01M |
| Avg Forecast | $90.40M | $86.20M | $79.60M | $75.40M | $75.66M | $73.31M | $64.81M | $60.55M | $53.50M | $50.73M | $42.95M | $37.40M | $35.50M | $25.49M | $15.62M | $10.58M | $17.07M | $19.89M | $17.49M | $15.52M | $16.16M | $15.56M | $14.62M | $14.80M | $15.05M | $15.22M | $14.98M | $13.39M | $3.22M | $2.09M |
| High Forecast | $90.40M | $86.20M | $79.60M | $75.40M | $75.66M | $74.67M | $64.81M | $60.55M | $57.12M | $50.73M | $42.95M | $37.40M | $35.50M | $25.49M | $15.62M | $10.58M | $17.07M | $19.89M | $17.49M | $15.52M | $16.16M | $15.56M | $14.62M | $14.80M | $15.05M | $15.22M | $14.98M | $13.39M | $3.86M | $2.51M |
| Low Forecast | $90.40M | $86.20M | $79.60M | $75.40M | $75.66M | $71.96M | $64.81M | $60.55M | $50.59M | $50.73M | $42.95M | $37.40M | $35.50M | $25.49M | $15.62M | $10.58M | $17.07M | $19.89M | $17.49M | $15.52M | $16.16M | $15.56M | $14.62M | $14.80M | $15.05M | $15.22M | $14.98M | $13.39M | $2.58M | $1.68M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | 1.09% | 1.01% | 1.13% | 1.09% | 1.02% | 1.29% | 1.21% | 1.13% | 0.73% | 1.12% | 1.33% | 1.12% | 1.14% | 0.99% | 1.03% | 1.10% | 1.06% | 0.96% | 1.00% | 1.30% | 1.08% | 1.44% |
MannKind's average Quarter revenue forecast for Mar 24 based on 4 analysts is $60.55M, with a low forecast of $60.55M, and a high forecast of $60.55M. MNKD's average Quarter revenue forecast represents a 3.55% increase compared to the company's last Quarter revenue of $58.47M (Dec 23).
MannKind EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | $10.63M | $5.10M | $3.38M | $-3.63M | $-8.25M | $-8.86M | $-20.99M | $-21.25M | $-21.95M | $-462.00K | $-30.97M | $-5.50M | $-23.20M | $-8.26M | $-7.03M | $-6.17M | $-11.15M | $-5.13M | $-10.12M | $-12.45M | $-27.48M | $-12.90M |
| Avg Forecast | $-43.56M | $-41.53M | $-38.35M | $-36.33M | $-36.45M | $-35.32M | $-31.23M | $-30.83M | $-25.78M | $-24.44M | $-20.69M | $-24.37M | $-13.09M | $-12.28M | $-7.53M | $-19.27M | $-8.23M | $-9.58M | $-8.43M | $-4.13M | $-7.78M | $-7.50M | $-7.04M | $-8.23M | $-7.25M | $-7.33M | $-7.22M | $-14.94M | $-25.09M | $-7.27M |
| High Forecast | $-43.56M | $-41.53M | $-38.35M | $-36.33M | $-36.45M | $-34.67M | $-31.23M | $-24.66M | $-24.38M | $-24.44M | $-20.69M | $-19.50M | $-10.47M | $-12.28M | $-7.53M | $-15.41M | $-8.23M | $-9.58M | $-8.43M | $-3.30M | $-7.78M | $-7.50M | $-7.04M | $-6.58M | $-7.25M | $-7.33M | $-7.22M | $-11.95M | $-20.07M | $-5.82M |
| Low Forecast | $-43.56M | $-41.53M | $-38.35M | $-36.33M | $-36.45M | $-35.98M | $-31.23M | $-37.00M | $-27.52M | $-24.44M | $-20.69M | $-29.25M | $-15.71M | $-12.28M | $-7.53M | $-23.12M | $-8.23M | $-9.58M | $-8.43M | $-4.95M | $-7.78M | $-7.50M | $-7.04M | $-9.88M | $-7.25M | $-7.33M | $-7.22M | $-17.93M | $-30.11M | $-8.72M |
| Surprise % | - | - | - | - | - | - | - | - | -0.41% | -0.21% | -0.16% | 0.15% | 0.63% | 0.72% | 2.79% | 1.10% | 2.67% | 0.05% | 3.68% | 1.33% | 2.98% | 1.10% | 1.00% | 0.75% | 1.54% | 0.70% | 1.40% | 0.83% | 1.10% | 1.77% |
4 analysts predict MNKD's average Quarter EBITDA for Mar 24 to be $-30.83M, with a high of $-24.66M and a low of $-37.00M. This is -389.92% lower than MannKind's previous annual EBITDA (Dec 23) of $10.63M.
MannKind Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| Net Income | - | - | - | - | - | - | - | - | $1.40M | $1.72M | $-5.26M | $-16.02M | $-23.23M | $-19.71M | $-31.47M | $-31.12M | $-32.20M | $-4.43M | $-35.52M | $-12.92M | $-26.41M | $-11.26M | $-10.25M | $-9.32M | $-14.26M | $-10.37M | $-12.39M | $-14.88M | $-30.39M | $-16.32M |
| Avg Forecast | $10.92M | $10.92M | $8.19M | $8.19M | $7.51M | $8.19M | $2.18M | $-41.60M | $910.10K | $-4.52M | $-10.38M | $-32.89M | $-16.73M | $-23.48M | $-25.67M | $-26.00M | $-18.30M | $-18.20M | $-12.51M | $-9.69M | $-10.71M | $-12.56M | $-14.20M | $-12.43M | $-18.02M | $-19.66M | $-20.48M | $-17.86M | $-27.74M | $-9.20M |
| High Forecast | $10.92M | $10.92M | $8.19M | $8.19M | $7.51M | $8.19M | $2.18M | $-33.28M | $910.10K | $-4.52M | $-10.38M | $-26.31M | $-13.39M | $-23.48M | $-25.67M | $-20.80M | $-18.30M | $-18.20M | $-12.51M | $-7.75M | $-10.71M | $-12.56M | $-14.20M | $-9.94M | $-18.02M | $-19.66M | $-20.48M | $-14.29M | $-22.19M | $-7.36M |
| Low Forecast | $10.92M | $10.92M | $8.19M | $8.19M | $7.51M | $6.14M | $2.18M | $-49.92M | $910.10K | $-4.52M | $-10.38M | $-39.46M | $-20.08M | $-23.48M | $-25.67M | $-31.20M | $-18.30M | $-18.20M | $-12.51M | $-11.62M | $-10.71M | $-12.56M | $-14.20M | $-14.92M | $-18.02M | $-19.66M | $-20.48M | $-21.43M | $-33.29M | $-11.04M |
| Surprise % | - | - | - | - | - | - | - | - | 1.54% | -0.38% | 0.51% | 0.49% | 1.39% | 0.84% | 1.23% | 1.20% | 1.76% | 0.24% | 2.84% | 1.33% | 2.46% | 0.90% | 0.72% | 0.75% | 0.79% | 0.53% | 0.60% | 0.83% | 1.10% | 1.77% |
MannKind's average Quarter net income forecast for Mar 24 is $-41.60M, with a range of $-49.92M to $-33.28M. MNKD's average Quarter net income forecast represents a -3069.50% decrease compared to the company's last Quarter net income of $1.40M (Dec 23).
MannKind SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| SG&A | - | - | - | - | - | - | - | - | $20.54M | $23.98M | $25.95M | $23.85M | $22.09M | $22.64M | $26.04M | $20.70M | $22.73M | $17.22M | $20.06M | $17.41M | $17.12M | $13.90M | $13.67M | $14.35M | $15.72M | $16.67M | $16.61M | $25.67M | $20.62M | $15.39M |
| Avg Forecast | $81.50M | $77.72M | $71.77M | $67.98M | $68.21M | $66.10M | $58.43M | $33.12M | $48.24M | $45.74M | $38.72M | $26.18M | $13.55M | $22.98M | $14.09M | $9.54M | $15.39M | $17.93M | $15.77M | $13.06M | $14.57M | $14.03M | $13.18M | $13.34M | $13.57M | $13.72M | $13.51M | $12.08M | $2.90M | $1.89M |
| High Forecast | $81.50M | $77.72M | $71.77M | $67.98M | $68.21M | $67.32M | $58.43M | $39.74M | $51.50M | $45.74M | $38.72M | $31.42M | $16.26M | $22.98M | $14.09M | $9.54M | $15.39M | $17.93M | $15.77M | $15.67M | $14.57M | $14.03M | $13.18M | $13.34M | $13.57M | $13.72M | $13.51M | $12.08M | $3.48M | $2.27M |
| Low Forecast | $81.50M | $77.72M | $71.77M | $67.98M | $68.21M | $64.88M | $58.43M | $26.50M | $45.61M | $45.74M | $38.72M | $20.95M | $10.84M | $22.98M | $14.09M | $9.54M | $15.39M | $17.93M | $15.77M | $10.45M | $14.57M | $14.03M | $13.18M | $13.34M | $13.57M | $13.72M | $13.51M | $12.08M | $2.32M | $1.51M |
| Surprise % | - | - | - | - | - | - | - | - | 0.43% | 0.52% | 0.67% | 0.91% | 1.63% | 0.99% | 1.85% | 2.17% | 1.48% | 0.96% | 1.27% | 1.33% | 1.18% | 0.99% | 1.04% | 1.08% | 1.16% | 1.21% | 1.23% | 2.13% | 7.10% | 8.15% |
MannKind's average Quarter SG&A projection for Mar 24 is $33.12M, based on 4 Wall Street analysts, with a range of $26.50M to $39.74M. The forecast indicates a 61.28% rise compared to MNKD last annual SG&A of $20.54M (Dec 23).
MannKind EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $0.01 | $-0.02 | $-0.06 | $-0.09 | $-0.08 | $-0.12 | $-0.12 | $-0.13 | $-0.02 | $-0.14 | $-0.05 | $-0.11 | $-0.05 | $-0.05 | $-0.04 | $-0.07 | $-0.05 | $-0.07 | $-0.08 | $-0.25 | $-0.17 |
| Avg Forecast | $0.04 | $0.04 | $0.03 | $0.03 | $0.03 | $0.03 | $0.01 | $0.03 | - | $-0.02 | $-0.04 | $-0.05 | $-0.05 | $-0.09 | $-0.09 | $-0.10 | $-0.07 | $-0.07 | $-0.05 | $-0.05 | $-0.04 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.07 | $-0.10 | $-0.21 | $-0.05 |
| High Forecast | $0.04 | $0.04 | $0.03 | $0.03 | $0.03 | $0.03 | $0.01 | $0.03 | - | $-0.02 | $-0.04 | $-0.05 | $-0.05 | $-0.09 | $-0.09 | $-0.10 | $-0.07 | $-0.07 | $-0.05 | $-0.05 | $-0.04 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.07 | $-0.10 | $-0.17 | $-0.04 |
| Low Forecast | $0.04 | $0.04 | $0.03 | $0.03 | $0.03 | $0.02 | $0.01 | $0.03 | - | $-0.02 | $-0.04 | $-0.05 | $-0.05 | $-0.09 | $-0.09 | $-0.10 | $-0.07 | $-0.07 | $-0.05 | $-0.05 | $-0.04 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.07 | $-0.10 | $-0.25 | $-0.05 |
| Surprise % | - | - | - | - | - | - | - | - | 1.29% | -0.39% | 0.52% | 1.21% | 1.72% | 0.88% | 1.28% | 1.22% | 1.94% | 0.30% | 3.05% | 1.09% | 2.80% | 1.09% | 0.96% | 0.69% | 1.06% | 0.69% | 0.93% | 0.80% | 1.19% | 3.40% |
According to 4 Wall Street analysts, MannKind's projected average Quarter EPS for Mar 24 is $0.03, with a low estimate of $0.03 and a high estimate of $0.03. This represents a 504.65% increase compared to MNKD previous annual EPS of - (Dec 23).
MannKind Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ELEV | Elevation Oncology | $0.52 | $9.00 | 1630.77% | Buy |
| SGMO | Sangamo Therapeutics | $1.74 | $12.00 | 589.66% | Buy |
| IMMP | Immutep | $1.83 | $8.00 | 337.16% | Buy |
| ADAP | Adaptimmune Therapeutics | $0.83 | $2.83 | 240.96% | Buy |
| LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| AFMD | Affimed | $3.27 | $7.50 | 129.36% | Buy |
| VSTM | Verastem | $3.90 | $8.33 | 113.59% | Buy |
| LEGN | Legend Biotech | $43.61 | $82.62 | 89.45% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $21.48 | $36.33 | 69.13% | Buy |
| LQDA | Liquidia | $10.46 | $17.17 | 64.15% | Buy |
| MNKD | MannKind | $7.09 | $11.00 | 55.15% | Buy |
| BMRN | BioMarin Pharmaceutical | $66.01 | $101.70 | 54.07% | Buy |
| SABS | SAB Biotherapeutics | $4.04 | $5.67 | 40.35% | Buy |
| TECH | Bio-Techne | $75.90 | $91.69 | 20.80% | Buy |
| PCVX | Vaxcyte | $106.49 | $124.14 | 16.57% | Buy |
| UTHR | United Therapeutics | $376.80 | $358.20 | -4.94% | Buy |
MNKD Forecast FAQ
Is MannKind a good buy?
Yes, according to 3 Wall Street analysts, MannKind (MNKD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of MNKD's total ratings.
What is MNKD's price target?
MannKind (MNKD) average price target is $11 with a range of $10 to $12, implying a 55.15% from its last price of $7.09. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will MannKind stock go up soon?
According to Wall Street analysts' prediction for MNKD stock, the company can go up by 55.15% (from the last price of $7.09 to the average price target of $11), up by 69.25% based on the highest stock price target, and up by 41.04% based on the lowest stock price target.
Can MannKind stock reach $11?
MNKD's highest twelve months analyst stock price target of $12 supports the claim that MannKind can reach $11 in the near future.
What are MannKind's analysts' financial forecasts?
MannKind's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $274.33M (high $275.69M, low $272.97M), average EBITDA is $-134M (high $-127M, low $-141M), average net income is $-23.717M (high $-15.397M, low $-34.086M), average SG&A $225.86M (high $233.71M, low $218.01M), and average EPS is $0.0915 (high $0.0915, low $0.084). MNKD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $331.6M (high $331.6M, low $331.6M), average EBITDA is $-160M (high $-160M, low $-160M), average net income is $38.23M (high $38.23M, low $38.23M), average SG&A $298.96M (high $298.96M, low $298.96M), and average EPS is $0.14 (high $0.14, low $0.14).
Did the MNKD's actual financial results beat the analysts' financial forecasts?
Based on MannKind's last annual report (Dec 2023), the company's revenue was $198.96M, beating the average analysts forecast of $184.58M by 7.79%. Apple's EBITDA was $8.68M, missing the average prediction of $-95.285M by -109.11%. The company's net income was $-11.938M, missing the average estimation of $-46.877M by -74.53%. Apple's SG&A was $94.31M, missing the average forecast of $158.88M by -40.64%. Lastly, the company's EPS was $-0.0447, missing the average prediction of $-0.101 by -55.96%. In terms of the last quarterly report (Dec 2023), MannKind's revenue was $58.47M, beating the average analysts' forecast of $53.5M by 9.29%. The company's EBITDA was $10.63M, missing the average prediction of $-25.779M by -141.25%. MannKind's net income was $1.4M, beating the average estimation of $910.1K by 53.94%. The company's SG&A was $20.54M, missing the average forecast of $48.24M by -57.43%. Lastly, the company's EPS was $0.0043, beating the average prediction of $0.00333 by 29.01%